ITGAM and breast cancer: For instance, using the RIG-I receptor agonist SLR14 results in an increased population of CD8+ T lymphocytes, NK cells, and CD11b+ cells in B16 Melanoma, suppressing tumor growth and subsequently generating immune memory and a systemic anti-tumor response.500 In a mouse model of breast cancer, the RIG-I receptor agonist SLR20 was observed to increase tumor-infiltrating lymphocytes and trigger the extrinsic apoptosis pathway and pyroptosis in breast cancer cells, mitigating tumor growth and metastasis.501